A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers

PHASE3CompletedINTERVENTIONAL
Enrollment

792

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

March 21, 2023

Study Completion Date

March 21, 2023

Conditions
Smoking Cessation
Interventions
DRUG

Cytisinicline

film-coated oral tablets containing 3 mg cytisinicline

DRUG

Placebo

film-coated oral tablets containing matched placebo

BEHAVIORAL

Behavioral support

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Trial Locations (12)

23606

Health Research of Hampton Toads, Inc, Newport News

28403

Trial Management Associates, LLC, Wilmington

32216

Jacksonville Center for Clinical Research, Jacksonville

32720

Accel Research Sites - DeLand Clinical Research Unit, DeLand

33912

Alliance for Multispecialty Research, LLC, Fort Myers

37203

Clinical Research Associates, Inc., Nashville

43212

Aventiv Research Inc, Columbus

44122

Velocity Clinical Research, Inc., Cleveland

47714

MediSphere Medical Research Center, LLC, Evansville

60523

Affinity Health Corp, Oak Brook

73069

Intend Research, Norman

08540

Global Medical Institutes LLC; Princeton Medical Institute, Princeton

Sponsors
All Listed Sponsors
lead

Achieve Life Sciences

INDUSTRY